420 related articles for article (PubMed ID: 17591078)
1. Association with 5'-untranslated region and response to interferon in chronic hepatitis C.
Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
Hepatogastroenterology; 2007; 54(75):854-7. PubMed ID: 17591078
[TBL] [Abstract][Full Text] [Related]
2. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
[TBL] [Abstract][Full Text] [Related]
3. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
[TBL] [Abstract][Full Text] [Related]
4. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.
Murayama M; Katano Y; Nakano I; Ishigami M; Hayashi K; Honda T; Hirooka Y; Itoh A; Goto H
J Med Virol; 2007 Jan; 79(1):35-40. PubMed ID: 17133546
[TBL] [Abstract][Full Text] [Related]
5. [Structural analysis of the PKR-binding region of HCV 1b samples from patients with chronic hepatitis C and the correlation with IFN-sensitivity].
Gervain J; Czibula A; Simon J; Kalmár T
Orv Hetil; 2003 Jun; 144(24):1179-84. PubMed ID: 12866147
[TBL] [Abstract][Full Text] [Related]
6. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.
Kurosaki M; Enomoto N; Murakami T; Sakuma I; Asahina Y; Yamamoto C; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
Hepatology; 1997 Mar; 25(3):750-3. PubMed ID: 9049230
[TBL] [Abstract][Full Text] [Related]
7. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C.
Fukutomi T; Fukutomi M; Iwao M; Watanabe H; Tanabe Y; Hiroshige K; Kinukawa N; Nakamuta M; Nawata H
Med Sci Monit; 2000; 6(4):692-8. PubMed ID: 11208393
[TBL] [Abstract][Full Text] [Related]
8. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon.
Kobayashi M; Watanabe K; Ishigami M; Murase K; Ito H; Ukai K; Yano M; Takagi K; Hattori M; Kakumu S; Yoshioka K
Am J Gastroenterol; 2002 Apr; 97(4):988-98. PubMed ID: 12003437
[TBL] [Abstract][Full Text] [Related]
9. Nucleotide sequence variations in the internal ribosome entry site of hepatitis C virus-1b: no association with efficacy of interferon therapy or serum HCV-RNA levels.
Yamamoto C; Enomoto N; Kurosaki M; Yu SH; Tazawa J; Izumi N; Marumo F; Sato C
Hepatology; 1997 Dec; 26(6):1616-20. PubMed ID: 9398006
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
[TBL] [Abstract][Full Text] [Related]
12. Correlation between translation efficiency and outcome of combination therapy in chronic hepatitis C genotype 3.
Yasmeen A; Hamid S; Granath FN; Lindström H; Elliott RM; Siddiqui AA; Persson MA
J Viral Hepat; 2006 Feb; 13(2):87-95. PubMed ID: 16436126
[TBL] [Abstract][Full Text] [Related]
13. Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 5' untranslated region using a matrix assisted laser desorption/ionization time of flight-based assay, restriction fragment mass polymorphism.
Oh HB; Kim SO; Cha CH; Hong SP; Folk WR; Kim KM; Suh DJ
J Med Virol; 2008 Oct; 80(10):1712-9. PubMed ID: 18712825
[TBL] [Abstract][Full Text] [Related]
14. The hepatitis C virus 5' untranslated region gene amplified by rapid amplification of cDNA ends and its secondary structure.
Qin ZX; Cong X; Jiang D; Ha MH; Chen HS; Wei L
Hepatobiliary Pancreat Dis Int; 2002 Aug; 1(3):368-72. PubMed ID: 14607708
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load.
Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Hirakawa M; Kobayashi M; Ikeda K; Kumada H
Intervirology; 2008; 51(4):265-9. PubMed ID: 18841028
[TBL] [Abstract][Full Text] [Related]
16. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes.
Frangeul L; Cresta P; Perrin M; Lunel F; Opolon P; Agut H; Huraux JM
Hepatology; 1998 Dec; 28(6):1674-9. PubMed ID: 9828234
[TBL] [Abstract][Full Text] [Related]
17. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.
Soler M; McHutchison JG; Kwoh TJ; Dorr FA; Pawlotsky JM
Antivir Ther; 2004 Dec; 9(6):953-68. PubMed ID: 15651754
[TBL] [Abstract][Full Text] [Related]
18. Impact of HIV on genomic variability in the 5'UTR of HCV in Indian patients with HCV/HIV co-infection.
Chaudhary A; Kukreti H; Pasha ST; Gupta S; Kumari M; Khare S; Lal S; Rai A
Intervirology; 2008; 51(4):224-9. PubMed ID: 18781077
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
[TBL] [Abstract][Full Text] [Related]
20. Method to detect substitutions in the interferon-sensitivity-determining region of hepatitis C virus 1b for prediction of response to interferon therapy.
Nishiguchi S; Ueda T; Itoh T; Enomoto M; Tanaka M; Tatsumi N; Fukuda K; Tamori A; Habu D; Takeda T; Otani S; Shiomi S
Hepatology; 2001 Jan; 33(1):241-7. PubMed ID: 11124842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
